Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.80 |
| ▸ | FLT1 | P17948 | 4/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | FLT4 | P35916 | 2/20 | 0.56 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | FYN | P06241 | 1/20 | 0.56 |
| ▸ | YES1 | P07947 | 1/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | HCK | P08631 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2841010 | 0.92 | KDR (0.67) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL3155848 | 0.89 | KDR (0.63) | KDRFLT1ABL1EGFRCSF1R | |
| Hydrochloric Acid SCHEMBL446342 | 0.89 | KDR (0.98) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL3150047 | 0.88 | KDR (0.62) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL3112552 | 0.86 | KDR (0.88) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL447738 | 0.86 | KDR (0.88) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL3154253 | 0.85 | KDR (0.70) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL427615 | 0.84 | KDR (0.84) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL427743 | 0.83 | KDR (1.00) | KDRFLT1ABL1EGFRCSF1R | |
| SCHEMBL2844186 | 0.83 | KDR (0.55) | KDRFLT1ABL1EGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | claimed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | claimed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | claimed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | claimed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | claimed |
| EP-2227453-B1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2016-03-09 | — | — | EP | disclosed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2227453-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| WO-2009049180-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
| WO-2004007458-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | AMGEN INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225106-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | KDR 15/4885FLT1 9/4885ABL1 547/4885 |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN3A, SCN2A | KDR 2379/4885FLT1 4455/4885ABL1 554/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | KDR 15/4885FLT1 9/4885ABL1 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.